Otsuka/Astex AML Candidate Guadecitabine Fails Phase III Trial

Otsuka Pharmaceutical and its Astex Pharmaceuticals subsidiary acknowledged last night that their cancer candidate guadecitabine (SGI-110) has failed a Phase III trial assessing the DNA methyltransferase inhibitor in a subgroup of patients with acute myeloid leukemia (AML).Guadecitabine missed the co-primary endpoints of the ASTRAL-1 trial ( NCT02348489 ) of superior benefit in complete response and overall survival compared with the control arm of physician’s choice of azacitidine, decita